Review
AIC. Dynavax
Affiliations
- PMID: 12833657
Item in Clipboard
Review
AIC. Dynavax
Curr Opin Investig Drugs.
2003 May.
Abstract
Dynavax is developing Amb a 1 immunostimulatory oligodeoxynucleotide-conjugate (AIC) as a potential immunotherapy for ragweed-induced seasonal allergy. By May 2001, phase II/III trials were underway in Canada and the US, and by March 2002, phase II trials were underway in France. In October 2002, Dynavax expected to commence a phase III trial in 2003.
Similar articles
-
Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.J Allergy Clin Immunol. 2004 Feb;113(2):235-41. doi: 10.1016/j.jaci.2003.11.001. J Allergy Clin Immunol. 2004. PMID: 14767435 Clinical Trial.
-
Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4+CD25+ T cells in the nasal mucosa of subjects with allergic rhinitis.Allergol Int. 2008 Dec;57(4):377-81. doi: 10.2332/allergolint.O-07-528. Epub 2008 Dec 1. Allergol Int. 2008. PMID: 18797179 Clinical Trial.
-
Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions.Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003;(94):304-12; discussion 312-3. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003. PMID: 15119051 Review.
-
Immunostimulatory DNA--Dynavax. AIC, Amb a 1 immunostimulatory conjugate, HBV-ISS, ISS 1018, ISS DNA, ISS DNA--dynavax, ISS1, ISS2.Drugs R D. 2002;3(3):193-6. doi: 10.2165/00126839-200203030-00011. Drugs R D. 2002. PMID: 12099166 Review. No abstract available.
-
Prevalence of IgE-binding to Art v 1, Art v 4 and Amb a 1 in mugwort-allergic patients.Int Arch Allergy Immunol. 2008;145(2):94-101. doi: 10.1159/000108134. Epub 2007 Sep 7. Int Arch Allergy Immunol. 2008. PMID: 17823540
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical